951127-28-9

Basic information

• Product Name: 6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran
• Synonyms: 6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran
• CAS NO: 951127-28-9
• Molecular Weight: 253.205
• Mol File: 951127-28-9.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran(951127-28-9)
• EPA Substance Registry System: 6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran(951127-28-9)

Safety Data

• Hazardous Substances Data: 951127-28-9(Hazardous Substances Data)

Usage

Description

6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran is a chemical compound characterized by its unique molecular structure, which features a difluorophenyl group, a methylidene bridge, and a nitro group attached to a 3,4-dihydro-2H-pyran core. 6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran serves as an important intermediate in the synthesis of various pharmaceutical agents.

Uses

Used in Pharmaceutical Industry:
6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran is used as a key intermediate in the synthesis of pyrrolo[3,4]pyrozole derivatives. These derivatives have potential therapeutic applications, particularly in the treatment of DPP-IV related diseases. DPP-IV, also known as dipeptidyl peptidase-4, is an enzyme involved in the regulation of glucose levels in the body. Inhibition of this enzyme can lead to improved glucose control and has been a target for the development of drugs to treat type 2 diabetes and other metabolic disorders.

Upstream product

• 951127-27-8 1-(2,5-difluorophenyl)-2-nitroethanone 
• 17616-43-2 3-iodo-2-(iodomethyl)-1-propene 
• 35730-09-7 2,5-difluorobenzoyl chloride 
• 951127-26-7 1-(2,5-difluorophenyl)-2-nitroethanol 
• 2646-90-4 2,5-difluorobenzaldehyde 

Downstream Products

• 1107693-22-0 C₁₆H₁₈F₂N₄O 
• 1456616-64-0 C₁₆H₁₈F₂N₄O 
• 1456616-65-1 C₁₆H₁₈F₂N₄O 
• 1456616-66-2 C₁₆H₁₈F₂N₄O 
• 1456616-67-3 C₁₆H₁₈F₂N₄O 
• 1456616-68-4 C₁₆H₁₈F₂N₄O 
• 951127-32-5 [(2R,3S)-5-hydroxy-5-hydroxymethyl-2-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-yl]carbamic acid tert-butyl ester 

Relevant articles and documents

Amino tetrahydropyrane derivatives

The invention provides amino tetrahydropyrane derivatives, pharmaceutically-acceptable salts, hydrates, solvates, stereoisomers and prodrugs of the amino tetrahydropyrane derivatives, a preparation method of the amino tetrahydropyrane derivatives and a pharmaceutical composition containing the compounds. A formula (I) of the amino tetrahydropyrane derivatives is as shown in the specification. The compounds are capable of inhibiting activity of DPP-IV (dipeptidyl peptidase IV) and can be used for treating dipeptidyl peptidase IV associated diseases such as diabetes, obesity and other metabolic diseases.

Inhibitor for dipeptidyl peptidase-IV

The invention provides an aminotetrahydropyran derivative with a general formula (I) as described in the specification, pharmaceutically acceptable salts, hydrates, solvates and stereoisomers thereof, a preparation method for the aminotetrahydropyran derivative, and a pharmaceutical composition containing the aminotetrahydropyran derivative. The aminotetrahydropyran derivative provided by the invention can inhibit the activity of dipeptidyl peptidase-IV(DPP-IV), and can be used for treatment of diseases related to dipeptidyl peptidase-IV, especially for treatment of diabetes.

2-PHENYL-5-HETEROCYCLYL-TETRAHYDRO-2H-PYRAN-3-AMINE COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND ITS ASSOCIATED DISORDERS

The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of diabetes mellitus (DM), obesity and other metabolic disorders. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.